Lisanti Capital Growth LLC Makes New $700,000 Investment in NewAmsterdam Pharma (NASDAQ:NAMS)

Lisanti Capital Growth LLC acquired a new stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 42,165 shares of the company's stock, valued at approximately $700,000.

Other large investors have also bought and sold shares of the company. Janus Henderson Group PLC bought a new position in NewAmsterdam Pharma in the 1st quarter worth $15,018,000. abrdn plc raised its holdings in shares of NewAmsterdam Pharma by 69.8% in the third quarter. abrdn plc now owns 129,060 shares of the company's stock valued at $2,142,000 after acquiring an additional 53,060 shares in the last quarter. Millennium Management LLC boosted its position in NewAmsterdam Pharma by 23.0% during the second quarter. Millennium Management LLC now owns 1,165,429 shares of the company's stock valued at $22,388,000 after purchasing an additional 217,902 shares in the last quarter. Banque Cantonale Vaudoise acquired a new position in shares of NewAmsterdam Pharma during the second quarter valued at about $38,000. Finally, Deerfield Management Company L.P. Series C lifted its position in NewAmsterdam Pharma by 30.3% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 869,250 shares of the company's stock worth $16,698,000 after acquiring an additional 202,250 shares during the period. 89.89% of the stock is owned by institutional investors.

Insider Transactions at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 45,000 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total value of $707,400.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 19.50% of the company's stock.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ:NAMS traded up $0.17 during midday trading on Tuesday, hitting $24.76. 629,985 shares of the stock were exchanged, compared to its average volume of 263,983. NewAmsterdam Pharma has a 52-week low of $8.64 and a 52-week high of $26.35. The business's fifty day simple moving average is $17.83 and its two-hundred day simple moving average is $18.50.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on NAMS shares. Needham & Company LLC reaffirmed a "buy" rating and set a $36.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, November 7th. Royal Bank of Canada reiterated an "outperform" rating and issued a $31.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $37.00 price objective on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $33.80.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.